Sandbox Reserved 1128
From Proteopedia
(Difference between revisions)
| Line 40: | Line 40: | ||
== References == | == References == | ||
<references/> | <references/> | ||
| - | |||
| - | |||
| - | |||
| - | This is a default text for your page ''''''. Click above on '''edit this page''' to modify. Be careful with the < and > signs. | ||
| - | You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue. | ||
Revision as of 13:30, 30 January 2016
| This Sandbox is Reserved from 15/12/2015, through 15/06/2016 for use in the course "Structural Biology" taught by Bruno Kieffer at the University of Strasbourg, ESBS. This reservation includes Sandbox Reserved 1120 through Sandbox Reserved 1159. |
To get started:
More help: Help:Editing |
Human Thioredoxin Reductase 1
| |||||||||||
References
- ↑ Mustacich D, Powis G. Thioredoxin reductase. Biochem J. 2000 Feb 15;346 Pt 1:1-8.
- ↑ Jurado J, Prieto-Alamo MJ, Madrid-Rísquez J, Pueyo C. Absolute gene expression patterns of thioredoxin and glutaredoxin redox systems in mouse. J Biol Chem. 2003 Nov 14;278(46):45546-54. Epub 2003 Sep 3.
- ↑ Holmgren A, Björnstedt M. Thioredoxin and thioredoxin reductase. Methods Enzymol. 1995;252:199-208.
- ↑ Oblong JE, Berggren M, Gasdaska PY, Powis G. Site-directed mutagenesis of active site cysteines in human thioredoxin produces competitive inhibitors of human thioredoxin reductase and elimination of mitogenic properties of thioredoxin. J Biol Chem. 1994 Apr 22;269(16):11714-20.
- ↑ Powis G, Montfort WR. Properties and biological activities of thioredoxins. Annu Rev Pharmacol Toxicol. 2001;41:261-95.
- ↑ Ueno M, Masutani H, Arai RJ, Yamauchi A, Hirota K, Sakai T, Inamoto T, Yamaoka Y, Yodoi J, Nikaido T. Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem. 1999 Dec 10;274(50):35809-15.
- ↑ Freemerman AJ, Gallegos A, Powis G. Nuclear factor kappaB transactivation is increased but is not involved in the proliferative effects of thioredoxin overexpression in MCF-7 breast cancer cells. Cancer Res. 1999 Aug 15;59(16):4090-4.
- ↑ Cassidy PB, Edes K, Nelson CC, Parsawar K, Fitzpatrick FA, Moos PJ. Thioredoxin reductase is required for the inactivation of tumor suppressor p53 and for apoptosis induced by endogenous electrophiles. Carcinogenesis. 2006 Dec;27(12):2538-49. Epub 2006 Jun 15.
- ↑ Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature. 1997 Sep 18;389(6648):300-5.
- ↑ Kabe Y, Ando K, Hirao S, Yoshida M, Handa H. Redox regulation of NF-kappaB activation: distinct redox regulation between the cytoplasm and the nucleus. Antioxid Redox Signal. 2005 Mar-Apr;7(3-4):395-403.
- ↑ Nakamura H. Extracellular functions of thioredoxin. Novartis Found Symp. 2008;291:184-92; discussion 192-5, 221-4.
- ↑ Bertini R, Howard OM, Dong HF, Oppenheim JJ, Bizzarri C, Sergi R, Caselli G, Pagliei S, Romines B, Wilshire JA, Mengozzi M, Nakamura H, Yodoi J, Pekkari K, Gurunath R, Holmgren A, Herzenberg LA, Herzenberg LA, Ghezzi P. Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells. J Exp Med. 1999 Jun 7;189(11):1783-9.
